MA39335A1 - Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone - Google Patents
Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazoloneInfo
- Publication number
- MA39335A1 MA39335A1 MA39335A MA39335A MA39335A1 MA 39335 A1 MA39335 A1 MA 39335A1 MA 39335 A MA39335 A MA 39335A MA 39335 A MA39335 A MA 39335A MA 39335 A1 MA39335 A1 MA 39335A1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrazolone
- mgat2 inhibitors
- inhibitors
- substituted
- substituted dihydropyridinone
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010092861 2-acylglycerol O-acyltransferase Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés de formule (i) : un stéréo-isomère, un tautomère, un sel pharmaceutiquement acceptable, un polymorphe, un solvate de ces derniers, toutes les variables de la formule étant telles que définies dans ce document. Ces composés sont des inhibiteurs de monoacylglycérol acyltransférase de type 2 (mgat2) qui peuvent être utilisés en tant que médicaments.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949490P | 2014-03-07 | 2014-03-07 | |
| PCT/US2015/018870 WO2015134699A1 (fr) | 2014-03-07 | 2015-03-05 | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39335A1 true MA39335A1 (fr) | 2017-09-29 |
| MA39335B1 MA39335B1 (fr) | 2019-12-31 |
Family
ID=52686513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39335A MA39335B1 (fr) | 2014-03-07 | 2015-03-05 | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9688656B2 (fr) |
| EP (1) | EP3114120B1 (fr) |
| JP (1) | JP6449919B2 (fr) |
| KR (1) | KR102336371B1 (fr) |
| CN (1) | CN106061968B (fr) |
| AU (1) | AU2015227140B2 (fr) |
| BR (1) | BR112016019487B1 (fr) |
| CA (1) | CA2941951C (fr) |
| CL (1) | CL2016002238A1 (fr) |
| CY (1) | CY1121746T1 (fr) |
| DK (1) | DK3114120T3 (fr) |
| EA (1) | EA030561B1 (fr) |
| ES (1) | ES2719713T3 (fr) |
| HR (1) | HRP20190668T1 (fr) |
| HU (1) | HUE044272T2 (fr) |
| IL (1) | IL247592B (fr) |
| LT (1) | LT3114120T (fr) |
| MA (1) | MA39335B1 (fr) |
| MX (1) | MX2016011223A (fr) |
| MY (1) | MY176921A (fr) |
| NZ (1) | NZ724890A (fr) |
| PE (1) | PE20161369A1 (fr) |
| PH (1) | PH12016501517B1 (fr) |
| PL (1) | PL3114120T3 (fr) |
| PT (1) | PT3114120T (fr) |
| RS (1) | RS58740B1 (fr) |
| SG (1) | SG11201607393XA (fr) |
| SI (1) | SI3114120T1 (fr) |
| SM (1) | SMT201900256T1 (fr) |
| TR (1) | TR201906325T4 (fr) |
| WO (1) | WO2015134699A1 (fr) |
| ZA (1) | ZA201606174B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791091B2 (en) | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
| MA39335B1 (fr) * | 2014-03-07 | 2019-12-31 | Bristol Myers Squibb Co | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone |
| WO2015191681A2 (fr) | 2014-06-11 | 2015-12-17 | Bristol-Myers Squibb Company | Pyridinones substituées utilisées comme inhibiteurs de mgat2 |
| CN105218518B (zh) * | 2015-09-15 | 2018-01-12 | 青岛科标检测研究院有限公司 | 一种可用于制备供热采暖系统清洗剂的化合物及其制备方法 |
| WO2017069224A1 (fr) * | 2015-10-22 | 2017-04-27 | 塩野義製薬株式会社 | Dérivé spiro hétérocyclique présentant une activité inhibitrice de mgat2 |
| EP3395798A4 (fr) * | 2015-12-21 | 2019-07-17 | Shionogi & Co., Ltd | Dérivé hétérocyclique non-aromatique présentant une activité inhibitrice de mgat2 |
| JP2020158390A (ja) * | 2017-06-20 | 2020-10-01 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体およびそれらを含有する医薬組成物 |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| MX2021008050A (es) | 2019-01-11 | 2021-08-05 | Shionogi & Co | Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2). |
| US20240374587A1 (en) * | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| EP4201923A1 (fr) | 2021-12-23 | 2023-06-28 | Karl-Franzens-Universität Graz | 2,3-dihydropyridine-4-ones 5-substitués et leur procédé de préparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US20100016365A1 (en) | 2008-07-17 | 2010-01-21 | Auspex Pharmaceuticals, Inc. | Substituted 4-amino-piperidines |
| US8791091B2 (en) | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
| KR102291444B1 (ko) | 2013-05-29 | 2021-08-18 | 브리스톨-마이어스 스큅 컴퍼니 | 디히드로피리디논 mgat2 억제제 |
| JP6498705B2 (ja) | 2014-03-07 | 2019-04-10 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 代謝障害の治療に用いるためのジヒドロピリジノンｍｇａｔ２阻害剤 |
| MA39335B1 (fr) * | 2014-03-07 | 2019-12-31 | Bristol Myers Squibb Co | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone |
-
2015
- 2015-03-05 MA MA39335A patent/MA39335B1/fr unknown
- 2015-03-05 SG SG11201607393XA patent/SG11201607393XA/en unknown
- 2015-03-05 CA CA2941951A patent/CA2941951C/fr active Active
- 2015-03-05 HR HRP20190668TT patent/HRP20190668T1/hr unknown
- 2015-03-05 US US15/123,773 patent/US9688656B2/en active Active
- 2015-03-05 BR BR112016019487-0A patent/BR112016019487B1/pt active IP Right Grant
- 2015-03-05 RS RS20190436A patent/RS58740B1/sr unknown
- 2015-03-05 SM SM20190256T patent/SMT201900256T1/it unknown
- 2015-03-05 ES ES15710686T patent/ES2719713T3/es active Active
- 2015-03-05 MX MX2016011223A patent/MX2016011223A/es active IP Right Grant
- 2015-03-05 EA EA201691670A patent/EA030561B1/ru not_active IP Right Cessation
- 2015-03-05 PL PL15710686T patent/PL3114120T3/pl unknown
- 2015-03-05 LT LTEP15710686.5T patent/LT3114120T/lt unknown
- 2015-03-05 CN CN201580012204.XA patent/CN106061968B/zh active Active
- 2015-03-05 WO PCT/US2015/018870 patent/WO2015134699A1/fr not_active Ceased
- 2015-03-05 JP JP2016573680A patent/JP6449919B2/ja active Active
- 2015-03-05 PE PE2016001576A patent/PE20161369A1/es active IP Right Grant
- 2015-03-05 PT PT15710686T patent/PT3114120T/pt unknown
- 2015-03-05 SI SI201530657T patent/SI3114120T1/sl unknown
- 2015-03-05 HU HUE15710686 patent/HUE044272T2/hu unknown
- 2015-03-05 NZ NZ72489015A patent/NZ724890A/en unknown
- 2015-03-05 EP EP15710686.5A patent/EP3114120B1/fr active Active
- 2015-03-05 TR TR2019/06325T patent/TR201906325T4/tr unknown
- 2015-03-05 DK DK15710686.5T patent/DK3114120T3/da active
- 2015-03-05 MY MYPI2016703163A patent/MY176921A/en unknown
- 2015-03-05 AU AU2015227140A patent/AU2015227140B2/en active Active
- 2015-03-05 KR KR1020167027385A patent/KR102336371B1/ko active Active
-
2016
- 2016-08-01 PH PH12016501517A patent/PH12016501517B1/en unknown
- 2016-09-01 IL IL247592A patent/IL247592B/en active IP Right Grant
- 2016-09-06 ZA ZA2016/06174A patent/ZA201606174B/en unknown
- 2016-09-06 CL CL2016002238A patent/CL2016002238A1/es unknown
-
2017
- 2017-05-23 US US15/602,515 patent/US9896431B2/en active Active
-
2018
- 2018-01-10 US US15/866,871 patent/US10093650B2/en active Active
- 2018-08-30 US US16/117,107 patent/US10329273B2/en active Active
-
2019
- 2019-05-08 CY CY20191100492T patent/CY1121746T1/el unknown
- 2019-05-09 US US16/407,441 patent/US10538505B2/en active Active
- 2019-11-26 US US16/695,239 patent/US11479538B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39335A1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
| MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
| EA202091500A1 (ru) | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa | |
| MA40302B1 (fr) | Dérivés de carbazole | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| BR112017019286A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável deste | |
| MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
| CY1118365T1 (el) | Διαμορφωτες διυδροπυραζολης του gpr40 | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
| SA520411406B1 (ar) | مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1 | |
| MA50356A (fr) | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 | |
| MA39983A (fr) | Dérivés de carboxamide | |
| MX362919B (es) | Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1]. | |
| SA521421354B1 (ar) | مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CO2018001383A2 (es) | Derivados de n-[piridin-4-il]metil]-4-{(1r)-1-[(3s)-3-metil-2,5-dioxopirrolidin-3-il]etil}benzamida como antagonistas del receptor cgrp” | |
| MA50093B1 (fr) | Composé pentacyclique | |
| JO3742B1 (ar) | مركب بيرانو داي بيريدين | |
| MA46039B1 (fr) | Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain | |
| MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| AR125853A2 (es) | Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico |